Delea, Thomas; Tappenden, Paul; Sofrygin, Oleg; … - In: The European Journal of Health Economics 13 (2012) 5, pp. 589-603
When compared against capecitabine alone, the addition of lapatinib has a cost-effectiveness ratio exceeding the threshold normally used by NICE. Compared with T + C, L + C is dominant in the base case and approximately equally likely to be cost-effective in probabilistic sensitivity...